Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,188 JPY | +0.22% | +2.48% | +20.03% |
Apr. 15 | MC Healthcare, Inc. acquired FreeIll Co., Ltd. from ORIX Corporation. | CI |
Apr. 04 | S&P Global Ratings Cuts Orix's Rating, Outlook Remains Stable | MT |
Strengths
- With a P/E ratio at 11.09 for the current year and 9.37 for next year, earnings multiples are highly attractive compared with competitors.
- The company appears to be poorly valued given its net asset value.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Lending
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.03% | 23.38B | B | ||
-6.84% | 49.88B | C+ | ||
-5.35% | 30.53B | C+ | ||
+63.34% | 29.08B | - | - | |
+16.71% | 17.94B | B | ||
-7.09% | 11.81B | C+ | ||
+21.38% | 11.27B | B- | ||
-28.99% | 8.31B | - | ||
+15.00% | 8.13B | C | ||
+36.46% | 6.39B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 8591 Stock
- Ratings ORIX Corporation